SCHEMBL4364047

SCHEMBL4364047

CSc1cccc2c(Cl)ccnc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.49
▸ ALDH1A1 P00352 6/20 0.49
▸ TDP1 Q9NUW8 4/20 0.49
▸ MEN1 O00255 3/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ LMNA P02545 3/20 0.47
▸ HSP90AA1 P07900 3/20 0.47
▸ MAPT P10636 3/20 0.47
▸ METAP2 P50579 2/20 0.47
▸ METAP1 P53582 2/20 0.47
▸ BRD4 O60885 1/20 0.47
▸ NR4A2 P43354 1/20 0.43
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ MMP14 P50281 3/20 0.42
▸ CYP3A4 P08684 3/20 0.42
▸ ALOX12 P18054 3/20 0.42
▸ HTT P42858 3/20 0.42
▸ TP53 P04637 2/20 0.42
▸ ALOX15 P16050 2/20 0.42
▸ SLC6A2 P23975 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2963509 0.79 PSMD14 (0.45) KDM4EALDH1A1TDP1MEN1KMT2A
SCHEMBL318769 0.77 NR4A2 (0.68) KDM4EALDH1A1TDP1MEN1KMT2A
SCHEMBL29410781 0.77 NR4A2 (0.68) KDM4EALDH1A1TDP1MEN1KMT2A
SCHEMBL13201607 0.76 SLC40A1 (0.47) MEN1KMT2AHSP90AA1HTR1APSMD14
SCHEMBL13409385 0.76 PSMD14 (0.40) TDP1LMNAHSP90AA1NR4A2CYP3A4
SCHEMBL317120 0.76 HTR1A (0.56) KDM4EALDH1A1TDP1MEN1KMT2A
SCHEMBL18539683 0.73 PSMD14 (0.77) KDM4ELMNANR4A2PSMD14L3MBTL1
SCHEMBL22288159 0.73 HSP90AA1 (0.48) KDM4EALDH1A1TDP1MEN1KMT2A
SCHEMBL29661831 0.73 HSP90AA1 (0.48) KDM4EALDH1A1TDP1MEN1KMT2A
SCHEMBL27051239 0.72 CYP1A2 (0.59) KDM4EALDH1A1TDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2072502-A1 Sulfoximide substituted chinolin and chinazolin derivatives as kinase inhibitors Bayer Schering Pharma Aktiengesellschaft (DE) 2009-06-24 — — EP disclosed
Send feedback